Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 937 to 948 of 948 entries
Sorted by: Best Match Show Resources per page
Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases.

The Journal of antimicrobial chemotherapy

Feng K, Jia N, Zhu P, Sy S, Liu Y, Dong D, Zhu S, Zhang J, Liu Y, Martins FS, Gong H, Lv Z, Yu M, Sy SKB, Zhu Y.
PMID: 34383928
J Antimicrob Chemother. 2021 Oct 11;76(11):2875-2883. doi: 10.1093/jac/dkab292.

OBJECTIVES: Ceftazidime/avibactam is not active against MBL-producing bacteria. Combining ceftazidime/avibactam or avibactam with aztreonam can counter the resistance of MBL-producing Enterobacterales. The aim of this study was to evaluate whether the addition of avibactam could reduce or close the...

Cite
Feng K, Jia N, Zhu P, et al. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases. J Antimicrob Chemother. 2021;76(11):2875-2883doi: 10.1093/jac/dkab292.
Feng, K., Jia, N., Zhu, P., Sy, S., Liu, Y., Dong, D., Zhu, S., Zhang, J., Liu, Y., Martins, F. S., Gong, H., Lv, Z., Yu, M., Sy, S. K. B., & Zhu, Y. (2021). Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases. The Journal of antimicrobial chemotherapy, 76(11), 2875-2883. https://doi.org/10.1093/jac/dkab292
Feng, Kun, et al. "Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases." The Journal of antimicrobial chemotherapy vol. 76,11 (2021): 2875-2883. doi: https://doi.org/10.1093/jac/dkab292
Feng K, Jia N, Zhu P, Sy S, Liu Y, Dong D, Zhu S, Zhang J, Liu Y, Martins FS, Gong H, Lv Z, Yu M, Sy SKB, Zhu Y. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases. J Antimicrob Chemother. 2021 Oct 11;76(11):2875-2883. doi: 10.1093/jac/dkab292. PMID: 34383928.
Copy Download .nbib Format: NLM
Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.

Journal of global antimicrobial resistance

Kang Y, Zhou Q, Cui J.
PMID: 34428596
J Glob Antimicrob Resist. 2021 Aug 21;27:67-71. doi: 10.1016/j.jgar.2021.07.020. Epub 2021 Aug 21.

OBJECTIVES: The objective of this study was to evaluate the efficacy of different dosing regimens of ceftazidime/avibactam (CZA) in patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) pulmonary infections.METHODS: A total of 70 KPC-Kp strains were isolated from sputum...

Cite
Kang Y, Zhou Q, Cui J. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China. J Glob Antimicrob Resist. 2021;27:67-71doi: 10.1016/j.jgar.2021.07.020.
Kang, Y., Zhou, Q., & Cui, J. (2021). Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China. Journal of global antimicrobial resistance, 2767-71. https://doi.org/10.1016/j.jgar.2021.07.020
Kang, Yixin, et al. "Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China." Journal of global antimicrobial resistance vol. 27 (2021): 67-71. doi: https://doi.org/10.1016/j.jgar.2021.07.020
Kang Y, Zhou Q, Cui J. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China. J Glob Antimicrob Resist. 2021 Aug 21;27:67-71. doi: 10.1016/j.jgar.2021.07.020. Epub 2021 Aug 21. PMID: 34428596.
Copy Download .nbib Format: NLM
Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report.

Pediatric nephrology (Berlin, Germany)

Bruno V, Tjon J, Lin S, Groves H, Kazmi K, Zappitelli M, Harvey E.
PMID: 34633526
Pediatr Nephrol. 2022 Jan;37(1):217-220. doi: 10.1007/s00467-021-05313-3. Epub 2021 Oct 11.

INTRODUCTION: Gordonia species, aerobic, weakly acid-fast, Gram-positive bacilli, are a rare cause of peritonitis in patients undergoing peritoneal dialysis (PD). We report the first pediatric case of PD-related peritonitis caused by Gordonia bronchialis.CASE PRESENTATION: A 13-year-old girl with chronic...

Cite
Bruno V, Tjon J, Lin S, et al. Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report. Pediatr Nephrol. 2021;37(1):217-220doi: 10.1007/s00467-021-05313-3.
Bruno, V., Tjon, J., Lin, S., Groves, H., Kazmi, K., Zappitelli, M., & Harvey, E. (2022). Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report. Pediatric nephrology (Berlin, Germany), 37(1), 217-220. https://doi.org/10.1007/s00467-021-05313-3
Bruno, Valentina, et al. "Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report." Pediatric nephrology (Berlin, Germany) vol. 37,1 (2022): 217-220. doi: https://doi.org/10.1007/s00467-021-05313-3
Bruno V, Tjon J, Lin S, Groves H, Kazmi K, Zappitelli M, Harvey E. Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report. Pediatr Nephrol. 2022 Jan;37(1):217-220. doi: 10.1007/s00467-021-05313-3. Epub 2021 Oct 11. PMID: 34633526; PMCID: PMC8503381.
Copy Download .nbib Format: NLM
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review.

Infectious diseases and therapy

Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P.
PMID: 34379310
Infect Dis Ther. 2021 Dec;10(4):1989-2034. doi: 10.1007/s40121-021-00507-6. Epub 2021 Aug 11.

INTRODUCTION: A systematic literature review was undertaken to evaluate real-world use of ceftazidime-avibactam for infections due to aerobic Gram-negative organisms in adults with limited treatment options.METHODS: Literature searches retrieved peer-reviewed publications and abstracts from major international infectious disease congresses...

Cite
Soriano A, Carmeli Y, Omrani AS, et al. Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infect Dis Ther. 2021;10(4):1989-2034doi: 10.1007/s40121-021-00507-6.
Soriano, A., Carmeli, Y., Omrani, A. S., Moore, L. S. P., Tawadrous, M., & Irani, P. (2021). Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infectious diseases and therapy, 10(4), 1989-2034. https://doi.org/10.1007/s40121-021-00507-6
Soriano, Alex, et al. "Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review." Infectious diseases and therapy vol. 10,4 (2021): 1989-2034. doi: https://doi.org/10.1007/s40121-021-00507-6
Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infect Dis Ther. 2021 Dec;10(4):1989-2034. doi: 10.1007/s40121-021-00507-6. Epub 2021 Aug 11. PMID: 34379310; PMCID: PMC8355581.
Copy Download .nbib Format: NLM
Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant .

Infection and drug resistance

Chen F, Zhong H, Yang T, Shen C, Deng Y, Han L, Chen X, Zhang H, Qian Y.
PMID: 34992387
Infect Drug Resist. 2021 Dec 21;14:5603-5612. doi: 10.2147/IDR.S342163. eCollection 2021.

BACKGROUND: Ceftazidime-avibactam (CZA) has been approved in vitro activity against carbapenem-resistant METHODS: LT recipients with CRKP infection who received CZA treatment were reviewed retrospectively, microbiological and clinical response, adverse events were also assessed. The primary outcome was 30-day mortality...

Cite
Chen F, Zhong H, Yang T, et al. Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant . Infect Drug Resist. 2021;14:5603-5612doi: 10.2147/IDR.S342163.
Chen, F., Zhong, H., Yang, T., Shen, C., Deng, Y., Han, L., Chen, X., Zhang, H., & Qian, Y. (2021). Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant . Infection and drug resistance, 145603-5612. https://doi.org/10.2147/IDR.S342163
Chen, Fang, et al. "Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant ." Infection and drug resistance vol. 14 (2021): 5603-5612. doi: https://doi.org/10.2147/IDR.S342163
Chen F, Zhong H, Yang T, Shen C, Deng Y, Han L, Chen X, Zhang H, Qian Y. Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant . Infect Drug Resist. 2021 Dec 21;14:5603-5612. doi: 10.2147/IDR.S342163. eCollection 2021. PMID: 34992387; PMCID: PMC8710070.
Copy Download .nbib Format: NLM
Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing .

Antibiotics (Basel, Switzerland)

Papadimitriou-Olivgeris M, Bartzavali C, Nikolopoulou A, Kolonitsiou F, Mplani V, Spiliopoulou I, Christofidou M, Fligou F, Marangos M.
PMID: 33228012
Antibiotics (Basel). 2020 Nov 19;9(11). doi: 10.3390/antibiotics9110828.

BACKGROUND: Tigecycline is a therapeutic option for carbapenemase-producing METHODS: Patients with monomicrobial bacteraemia due to CP-Kp that received appropriate targeted monotherapy or no appropriate treatment were included. Primary outcome was 30-day mortality. MICs of meropenem, tigecycline, and ceftazidime/avibactam were...

Cite
Papadimitriou-Olivgeris M, Bartzavali C, Nikolopoulou A, et al. Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing . Antibiotics (Basel). 2020;9(11)doi: 10.3390/antibiotics9110828.
Papadimitriou-Olivgeris, M., Bartzavali, C., Nikolopoulou, A., Kolonitsiou, F., Mplani, V., Spiliopoulou, I., Christofidou, M., Fligou, F., & Marangos, M. (2020). Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing . Antibiotics (Basel, Switzerland), 9(11), . https://doi.org/10.3390/antibiotics9110828
Papadimitriou-Olivgeris, Matthaios, et al. "Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing ." Antibiotics (Basel, Switzerland) vol. 9,11 (2020). doi: https://doi.org/10.3390/antibiotics9110828
Papadimitriou-Olivgeris M, Bartzavali C, Nikolopoulou A, Kolonitsiou F, Mplani V, Spiliopoulou I, Christofidou M, Fligou F, Marangos M. Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing . Antibiotics (Basel). 2020 Nov 19;9(11). doi: 10.3390/antibiotics9110828. PMID: 33228012; PMCID: PMC7699267.
Copy Download .nbib Format: NLM
Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis.

American journal of ophthalmology case reports

Babalola OE.
PMID: 33251375
Am J Ophthalmol Case Rep. 2020 Oct 17;20:100974. doi: 10.1016/j.ajoc.2020.100974. eCollection 2020 Dec.

PURPOSE: Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including OBSERVATIONS: An 84-year-old man who had phacoemulsification surgery and anterior chamber intraocular lens due to posterior...

Cite
Babalola OE. Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis. Am J Ophthalmol Case Rep. 2020;20:100974doi: 10.1016/j.ajoc.2020.100974.
Babalola, O. E. (2020). Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis. American journal of ophthalmology case reports, 20100974. https://doi.org/10.1016/j.ajoc.2020.100974
Babalola, Olufemi Emmanuel. "Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis." American journal of ophthalmology case reports vol. 20 (2020): 100974. doi: https://doi.org/10.1016/j.ajoc.2020.100974
Babalola OE. Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis. Am J Ophthalmol Case Rep. 2020 Oct 17;20:100974. doi: 10.1016/j.ajoc.2020.100974. eCollection 2020 Dec. PMID: 33251375; PMCID: PMC7680698.
Copy Download .nbib Format: NLM
KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.

Antimicrobial agents and chemotherapy

Jousset AB, Oueslati S, Emeraud C, Bonnin RA, Dortet L, Iorga BI, Naas T.
PMID: 34606331
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0116021. doi: 10.1128/AAC.01160-21. Epub 2021 Oct 04.

Resistance to the ceftazidime (CAZ)-avibactam (AVI) combination is increasingly being reported. Here, we report a CAZ-AVI-resistant Klebsiella pneumoniae strain belonging to the high-risk sequence type 307 (ST307) clone and producing Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of...

Cite
Jousset AB, Oueslati S, Emeraud C, et al. KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate. Antimicrob Agents Chemother. 2021;65(12):e0116021doi: 10.1128/AAC.01160-21.
Jousset, A. B., Oueslati, S., Emeraud, C., Bonnin, R. A., Dortet, L., Iorga, B. I., & Naas, T. (2021). KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate. Antimicrobial agents and chemotherapy, 65(12), e0116021. https://doi.org/10.1128/AAC.01160-21
Jousset, Agnès B, et al. "KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate." Antimicrobial agents and chemotherapy vol. 65,12 (2021): e0116021. doi: https://doi.org/10.1128/AAC.01160-21
Jousset AB, Oueslati S, Emeraud C, Bonnin RA, Dortet L, Iorga BI, Naas T. KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0116021. doi: 10.1128/AAC.01160-21. Epub 2021 Oct 04. PMID: 34606331; PMCID: PMC8597731.
Copy Download .nbib Format: NLM
In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam.

Journal of global antimicrobial resistance

Sribenjalux W, Wonglakorn L, Meesing A.
PMID: 34922057
J Glob Antimicrob Resist. 2021 Dec 16;28:8-11. doi: 10.1016/j.jgar.2021.11.015. Epub 2021 Dec 16.

OBJECTIVES: Treatment options are limited for melioidosis patients who develop nosocomial infections due to extensively drug-resistant (XDR) Gram-negative bacilli. Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA), which have activity against XDR Gram-negative bacteria, are two potential options. Data regarding the susceptibility...

Cite
Sribenjalux W, Wonglakorn L, Meesing A. In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam. J Glob Antimicrob Resist. 2021;28:8-11doi: 10.1016/j.jgar.2021.11.015.
Sribenjalux, W., Wonglakorn, L., & Meesing, A. (2021). In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam. Journal of global antimicrobial resistance, 288-11. https://doi.org/10.1016/j.jgar.2021.11.015
Sribenjalux, Wantin, et al. "In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam." Journal of global antimicrobial resistance vol. 28 (2021): 8-11. doi: https://doi.org/10.1016/j.jgar.2021.11.015
Sribenjalux W, Wonglakorn L, Meesing A. In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam. J Glob Antimicrob Resist. 2021 Dec 16;28:8-11. doi: 10.1016/j.jgar.2021.11.015. Epub 2021 Dec 16. PMID: 34922057.
Copy Download .nbib Format: NLM
In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam.

Journal of global antimicrobial resistance

Sribenjalux W, Wonglakorn L, Meesing A.
PMID: 34922057
J Glob Antimicrob Resist. 2021 Dec 16;28:8-11. doi: 10.1016/j.jgar.2021.11.015. Epub 2021 Dec 16.

OBJECTIVES: Treatment options are limited for melioidosis patients who develop nosocomial infections due to extensively drug-resistant (XDR) Gram-negative bacilli. Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA), which have activity against XDR Gram-negative bacteria, are two potential options. Data regarding the susceptibility...

Cite
Sribenjalux W, Wonglakorn L, Meesing A. In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam. J Glob Antimicrob Resist. 2021;28:8-11doi: 10.1016/j.jgar.2021.11.015.
Sribenjalux, W., Wonglakorn, L., & Meesing, A. (2021). In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam. Journal of global antimicrobial resistance, 288-11. https://doi.org/10.1016/j.jgar.2021.11.015
Sribenjalux, Wantin, et al. "In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam." Journal of global antimicrobial resistance vol. 28 (2021): 8-11. doi: https://doi.org/10.1016/j.jgar.2021.11.015
Sribenjalux W, Wonglakorn L, Meesing A. In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam. J Glob Antimicrob Resist. 2021 Dec 16;28:8-11. doi: 10.1016/j.jgar.2021.11.015. Epub 2021 Dec 16. PMID: 34922057.
Copy Download .nbib Format: NLM
Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey.

Acta microbiologica et immunologica Hungarica

Ozger HS, Evren E, Yildiz SS, Erol C, Bayrakdar F, Azap O, Azap A, Senol E.
PMID: 34324428
Acta Microbiol Immunol Hung. 2021 Jul 29; doi: 10.1556/030.2021.01525. Epub 2021 Jul 29.

This study aimed to detect carbapenemase genes and to determine the in vitro susceptibility of Ceftazidime-Avibactam (CZA) in Enterobacterales isolates. Carbapenemase genes were detected by polymerase chain reaction. CZA sensitivity of isolates was evaluated with broth microdilution (BMD) and...

Cite
Ozger HS, Evren E, Yildiz SS, et al. Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey. Acta Microbiol Immunol Hung. 2021;doi: 10.1556/030.2021.01525.
Ozger, H. S., Evren, E., Yildiz, S. S., Erol, C., Bayrakdar, F., Azap, O., Azap, A., & Senol, E. (2021). Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey. Acta microbiologica et immunologica Hungarica, . https://doi.org/10.1556/030.2021.01525
Ozger, Hasan Selcuk, et al. "Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey." Acta microbiologica et immunologica Hungarica vol. (2021). doi: https://doi.org/10.1556/030.2021.01525
Ozger HS, Evren E, Yildiz SS, Erol C, Bayrakdar F, Azap O, Azap A, Senol E. Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey. Acta Microbiol Immunol Hung. 2021 Jul 29; doi: 10.1556/030.2021.01525. Epub 2021 Jul 29. PMID: 34324428.
Copy Download .nbib Format: NLM
Characterization of .

JAC-antimicrobial resistance

Sader HS, Mendes RE, Doyle TB, Davis AP, Castanheira M.
PMID: 34430873
JAC Antimicrob Resist. 2021 Aug 20;3(3):dlab136. doi: 10.1093/jacamr/dlab136. eCollection 2021 Sep.

OBJECTIVES: To evaluate the antimicrobial susceptibility and resistance mechanisms to β-lactams among METHODS: 2571 RESULTS: Overall susceptibility to ceftazidime and cefepime were 73.9% and 91.2% among CONCLUSIONS: Hyperproduction of chromosomal AmpC appears to be the most common mechanism of...

Cite
Sader HS, Mendes RE, Doyle TB, et al. Characterization of . JAC Antimicrob Resist. 2021;3(3):dlab136doi: 10.1093/jacamr/dlab136.
Sader, H. S., Mendes, R. E., Doyle, T. B., Davis, A. P., & Castanheira, M. (2021). Characterization of . JAC-antimicrobial resistance, 3(3), dlab136. https://doi.org/10.1093/jacamr/dlab136
Sader, Helio S, et al. "Characterization of ." JAC-antimicrobial resistance vol. 3,3 (2021): dlab136. doi: https://doi.org/10.1093/jacamr/dlab136
Sader HS, Mendes RE, Doyle TB, Davis AP, Castanheira M. Characterization of . JAC Antimicrob Resist. 2021 Aug 20;3(3):dlab136. doi: 10.1093/jacamr/dlab136. eCollection 2021 Sep. PMID: 34430873; PMCID: PMC8378278.
Copy Download .nbib Format: NLM
Showing 937 to 948 of 948 entries